Pharma News

Apricus Biosciences, Inc a biopharmaceutical company advancing innovative medicines in urology and rheumatology,  announced the outcome of its end-of-review meeting with the U.S. Food and Drug Administration (FDA) on the New Drug Application (NDA) for Vitaros™ (alprostadil, DDAIP.HCl), a topical cream for the treatment of erectile dysfunction.

Perrigo Company plc and its partner Dexcel Pharma Technologies, Ltd., announced the launch of store brand Omeprazole Delayed Release Orally Disintegrating Tablets 20mg (Omeprazole ODT), an over-the-counter (OTC) medication to treat frequent heartburn. Omeprazole ODT is an FDA-approved medication, featuring MelTech™ melt-in-your-mouth technology, that dissolves in the mouth without water. This product is packaged and marketed as a store brand or retailer 'own label' brand and will provide consumers with a high-quality option for treating frequent heartburn.

Novel technologies are being sought to replace the traditional pesticides used to protect plants, particularly edible plants such as cereals. A new collaborative project between the University of Helsinki and the French National Centre for Scientific Research (CNRS) is shedding light on the efficacy of environmentally friendly RNA-based vaccines that protect plants from diseases and pests.

Blocking the activity of an enzyme that has a key role in the generation of recurring seizures may provide a new way to treat epilepsy that is resistant to anti-seizure drugs, according to a study of rats and mice published in JNeurosci.

Talent demand in India grew by 8% in March 2018. This is the highest growth registered by the recruitment index in the last four months. Compared to last year (from March 2017- March 2018) this year has registered a 9% increase in overall talent demand.  RecruiteX – a monthly hiring trend report by recruitment portal TimesJobs - noted that key industries and functional areas posted a significant rise in talent demand and contributed to this phenomenal rise of 8% in hiring activities in March 2018. Talent demand was highest for professionals with 10-20 years of experience.

Generic developers looking to apply the recently proposed draft US Pharmacopoeia (USP) monograph for Albuterol Inhalation Aerosols will find relevant new testing equipment at the Copley Scientific stand at Respiratory Drug Delivery 2018 (April 22nd to 26th, Tucson, Arizona). The new TPK™ 2100 Critical Flow Controller, a highly automated unit for reproducible, cost-efficient dry powder inhaler (DPI) testing, will also make its US debut. Copley Scientific is proud to be sponsoring this key event in the inhalation calendar and experts from the company will be in attendance throughout to discuss any aspect of inhaler testing.

Eisai Co., Ltd. has announced that it has submitted to the U.S. Food and Drug Administration (FDA) a supplemental New Drug Application (sNDA) for Eisai’s antiepileptic drug (AED) Fycompa® (perampanel) seeking approval for an indication expansion to cover pediatric patients with epilepsy.

Biogen Inc and its partner Samsung Bioepis announced today an agreement with AbbVie  for the commercialization of IMRALDI, a biosimilar referencing HUMIRA® (adalimumab). Under terms of the agreement, AbbVie will grant patent licenses for the use and sale of IMRALDI in Europe, on a country-by-country basis, and Biogen and Samsung Bioepis will make royalty payments to AbbVie. The companies have agreed to dismiss all pending patent litigation.